Banco Santander S.A. Sells 1,382 Shares of Novo Nordisk A/S (NYSE:NVO)

Banco Santander S.A. reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 68,871 shares of the company’s stock after selling 1,382 shares during the period. Banco Santander S.A.’s holdings in Novo Nordisk A/S were worth $8,200,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blackhawk Capital Partners LLC. boosted its holdings in shares of Novo Nordisk A/S by 4.1% in the 3rd quarter. Blackhawk Capital Partners LLC. now owns 6,411 shares of the company’s stock worth $763,000 after purchasing an additional 251 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Novo Nordisk A/S by 2.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 79,660 shares of the company’s stock worth $9,485,000 after buying an additional 2,166 shares during the last quarter. LPL Financial LLC boosted its stake in Novo Nordisk A/S by 3.6% in the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after buying an additional 47,496 shares in the last quarter. Citizens Financial Group Inc. RI grew its position in Novo Nordisk A/S by 1.9% during the third quarter. Citizens Financial Group Inc. RI now owns 14,301 shares of the company’s stock valued at $1,703,000 after acquiring an additional 263 shares during the last quarter. Finally, EagleClaw Capital Managment LLC raised its stake in shares of Novo Nordisk A/S by 4.1% during the third quarter. EagleClaw Capital Managment LLC now owns 65,850 shares of the company’s stock worth $7,841,000 after acquiring an additional 2,575 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $102.77 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $116.12 and a 200-day moving average price of $128.92. The company has a market cap of $461.18 billion, a price-to-earnings ratio of 33.26, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.